NASDAQ:EDSA
Edesa Biotech, Inc. Stock News
$4.22
+0.0100 (+0.238%)
At Close: Jul 03, 2024
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
08:20am, Monday, 24'th Jun 2024
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expecte
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
04:15pm, Friday, 10'th May 2024
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
09:00am, Thursday, 11'th Apr 2024
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 02'nd Apr 2024
TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
04:30pm, Thursday, 21'st Mar 2024
TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech to Participate in Barclays Global Healthcare Conference
08:45am, Thursday, 07'th Mar 2024
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech to Participate in Upcoming Dermatology Meetings
04:30pm, Monday, 04'th Mar 2024
TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
04:15pm, Friday, 09'th Feb 2024
TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dis
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
04:15pm, Thursday, 04'th Jan 2024
TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dise
Edesa Biotech Reports Fiscal Year 2023 Results
04:10pm, Friday, 15'th Dec 2023
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory di
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
04:05pm, Monday, 20'th Nov 2023
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:
Edesa Biotech to Present at Dermatology Drug Development Summit
04:05pm, Thursday, 26'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug
09:10am, Wednesday, 25'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that He
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
12:15pm, Thursday, 12'th Oct 2023
Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-s
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
12:10pm, Thursday, 12'th Oct 2023
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitmen
